Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)

Filter

Mar 2023 | From Akero Therapeutics

Efruxifermin, a long-acting, bivalent FGF21 analog, normalized noninvasive measures of liver injury, fibrosis, and metabolic health in patients with NASH and F2/F3 fibrosis over 24 weeks

Mar 2023 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrated improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

Nov 2022 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrates improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

Aug 2022 | From Akero Therapeutics

Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health

Aug 2022 | From Akero Therapeutics

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis in NASH patients across PNPLA3 genotypes: a post hoc analysis of the Ph2a BALANCED study

Jun 2022 | From Akero Therapeutics

Efruxifermin (EFX), a long-acting FGF21 analog as a therapy for NASH

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment significantly reduced markers of collagen synthesis and fibrosis and normalized levels of Pro-C3 in patients with livery fibrosis associated with NASH

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.